The FDA recalls adulterated Choice Irish Cream Flavoured Drink containing an erectile dysfunction drug.
The FDA recalls adulterated Choice Irish Cream Flavoured Drink containing an erectile dysfunction drug.
The Food and Drugs Authority (FDA) has issued an immediate recall of all Choice Irish Cream Flavoured Drink from the market after laboratory analysis confirmed that the product had been adulterated with Sildenafil Citrate.
Sildenafil Citrate is a medicine that is used only after it has been prescribed by a medical doctor for the treatment of erectile dysfunction and pulmonary arterial hypertension.
In a statement released on November 5, 2025, the FDA explained that the drink, manufactured by 1 Africa Industries Limited, was registered as an alcoholic drink and must not contain any drug substances.
The presence of Sildenafil Citrate, a Phosphodiesterase Type 5 (PDE5) inhibitor, in the beverage poses serious public health risks, particularly because it was undeclared on the label.
According to the FDA, consumption of Sildenafil without medical supervision poses severe health and safety risks, especially for individuals using medications like nitroglycerine. The combination can cause a sudden and dangerous drop in blood pressure, potentially leading to heart attacks or strokes.
Beyond these risks, the FDA warned that the use of Sildenafil could also lead to painful, prolonged erections and psychological dependence, loss of vision or hearing, further endangering consumers’ well-being.
“The public is therefore strongly advised to refrain from purchasing or consuming this product,” the statement read.
The Authority is collaborating with 1 Africa Industries Limited to withdraw the product from the market for safe disposal, while appropriate regulatory actions are being initiated, as such adulteration of food products constitutes an offence and is in violation of Section 100 (4) of the Public Health Act, 2012 (Act 851).
The FDA further advised consumers, retailers, and distributors to comply with the recall directive and report any continued sale of the product to the nearest FDA office.
